Want to see AU:MAP full AI Analyst Report?
Top Page
Microba Life Sciences Limited
(Sydney:MAP)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.04
â–¼(-40.00% Downside)
Action:Reiterated
Date:10/24/26
The score is primarily held down by weak financial performance—persistent large losses, deteriorating profitability in 2026, and ongoing negative operating/free cash flow—despite relatively manageable leverage on the balance sheet. Technicals also detract given the stock trades below all key moving averages with negative MACD, while valuation provides limited support due to a negative P/E and no dividend yield.
Positive Factors
Manageable Leverage
Low leverage reduces near-term solvency pressure and preserves greater financial flexibility than a highly debt-funded model. This provides the company with more capacity to manage operating volatility and pursue its microbiome platform opportunities while losses remain elevated.
Negative Factors
Persistent Unprofitability
Deeply negative margins show that the current revenue base does not yet cover the cost structure, limiting the company’s ability to convert commercial activity into durable earnings. Continued operating losses could constrain investment capacity and make the path to sustainable profitability uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Low leverage reduces near-term solvency pressure and preserves greater financial flexibility than a highly debt-funded model. This provides the company with more capacity to manage operating volatility and pursue its microbiome platform opportunities while losses remain elevated.
Read all positive factors
Microba Life Sciences Limited (MAP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$26.00M
Dividend YieldN/A
Average Volume (3M)509.91K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth-5.81%
EPS Growth-3.60%
CountryAU
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.03
Shares Outstanding717,117,250
10 Day Avg. Volume328,993
30 Day Avg. Volume509,914
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)0.89
Price to Sales (P/S)1.47
P/FCF Ratio-1.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside33.33% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$17.70M
Microba Life Sciences Limited Business Overview & Revenue Model
Company Description
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across ke...
How the Company Makes Money
null...
Microba Life Sciences Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
21
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.76M | 15.67M | 12.09M | 5.42M | 4.69M |
| Gross Profit | -11.74M | 7.44M | 5.91M | -6.77M | 2.37M |
| EBITDA | -15.89M | -10.51M | -17.10M | -17.07M | -9.86M |
| Net Income | -20.72M | -14.94M | -19.94M | -12.68M | -11.47M |
Balance Sheet | |||||
| Total Assets | 39.81M | 47.44M | 58.04M | 46.95M | 39.48M |
| Cash, Cash Equivalents and Short-Term Investments | 7.95M | 11.74M | 20.89M | 32.04M | 30.79M |
| Total Debt | 4.11M | 3.23M | 1.58M | 1.14M | 1.33M |
| Total Liabilities | 15.43M | 14.94M | 16.82M | 8.23M | 5.94M |
| Stockholders Equity | 24.38M | 32.49M | 41.22M | 38.57M | 33.54M |
Cash Flow | |||||
| Free Cash Flow | -12.61M | -14.91M | -19.95M | -15.43M | -12.32M |
| Operating Cash Flow | -12.37M | -12.01M | -15.57M | -12.39M | -10.45M |
| Investing Cash Flow | -3.80M | -2.83M | -13.95M | -3.00M | -1.73M |
| Financing Cash Flow | 12.76M | 5.58M | 18.39M | 16.68M | 29.22M |
Microba Life Sciences Limited Technical Analysis
Negative
0.06
Price Trends
0.05
Negative
0.05
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
33.09
Neutral
47.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MAP, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.09 is Neutral, neither overbought nor oversold. The STOCH value of 47.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MAP.
Microba Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$29.49M | -3.98 | -881.94% | ― | 743.51% | -1.52% | |
47 Neutral | AU$17.94M | -1.28 | -35.10% | ― | -9.10% | 31.75% | |
43 Neutral | AU$26.00M | -1.01 | -75.96% | ― | -5.81% | -3.60% | |
41 Neutral | AU$23.66M | -3.73 | -205.17% | ― | 239.64% | -37.21% | |
41 Neutral | AU$58.30M | -5.97 | -35.89% | ― | 1.36% | 39.13% |
* Healthcare Sector Average
AU:MAP
Microba Life Sciences Limited
0.04
-0.04
-55.13%
AU:GTG
Genetic Technologies
―
―
―
AU:BDX
BCAL Diagnostics Limited
0.08
>-0.01
-11.11%
AU:RHY
Rhythm Biosciences Ltd.
0.07
-0.03
-33.67%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.06
-0.15
-71.22%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.25
-75.69%
Microba Life Sciences Limited Corporate Events
Microba options lapse, trimming future equity overhang
Oct 22, 2026
Microba Life Sciences has announced the lapse of 669,565 MAPAO options, which were scheduled to expire in February 2029 at an exercise price of $0.379, after conditions attached to these options were not met or became incapable of being satisfied....
Microba Life Sciences Plans 25 Million-Share ASX Placement
Oct 19, 2026
Microba Life Sciences Limited has announced a proposed placement of up to 25,000,000 ordinary fully paid shares on the ASX. The new securities are scheduled for issue on 23 December 2026, reflecting the company’s intention to raise additiona...
Microba Life Sciences Plans Major Share Placement to Raise Capital
Oct 19, 2026
Microba Life Sciences Limited, an ASX-listed life sciences company trading under the code MAP, operates in the microbiome science and biotechnology space. The business targets healthcare and related markets, leveraging public equity issuance to fu...
Microba raises $2m, deepens cost cuts ahead of Genetic Signatures merger
Oct 19, 2026
Microba Life Sciences has secured firm commitments for a $2.025 million two-tranche equity placement at $0.04 per share, backed by major shareholder Sonic Healthcare, institutional investors Perennial Partners and Thorney, and Microba directors, t...
Microba Sets 2026 AGM Date and Opens Nominations for Board Positions
Oct 13, 2026
Microba Life Sciences has scheduled its 2026 Annual General Meeting for 11:30 a.m. AEST on 27 November 2026 at Thomsons, Level 28, 1 Eagle Street in Brisbane, Queensland. The formal notice of meeting will be released to the market in late October ...
Microba Life Sciences Cuts Outstanding Options After Lapse of Conditional Rights
Oct 13, 2026
Microba Life Sciences Limited has notified the market of the cessation of several tranches of employee or incentive options, following the lapse of conditional rights where specified performance or vesting conditions were not satisfied. The affect...
Microba launches GI Navigator gut test in Australia and UK
Oct 6, 2026
Microba Life Sciences has launched GI Navigator, a clinical gut test now available to healthcare practitioners in Australia and the United Kingdom, aimed at making microbiome testing practical for general practitioners and gastroenterologists. The...
Microba Life Sciences Widens Annual Loss as Revenue Falls and Asset Backing Shrinks
Aug 31, 2026
Microba Life Sciences reported a 5.8% decline in revenues from ordinary activities to $14.76 million for the year ended 30 June 2026, while its net loss after tax widened 38.7% to $20.72 million. The company did not pay or declare any dividends fo...
Microba Details Compliance With ASX Corporate Governance Standards
Aug 31, 2026
Microba Life Sciences Limited, an ASX-listed life sciences company specialising in microbiome technologies, has outlined its adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The company operates under a for...
Microba tightens governance as it readies for updated ASX standards
Aug 31, 2026
Microba Life Sciences Limited operates in the Australian life sciences sector, specialising in microbiome analysis and related diagnostic services, and is listed on the ASX. Its business model depends heavily on regulatory compliance, transparent ...
Genetic Signatures and Microba in Talks Over Infectious Disease Diagnostics Merger
Aug 26, 2026
Genetic Signatures and Microba Life Sciences, both ASX-listed diagnostics players, are in preliminary talks over a potential merger that would create a larger infectious disease and microbiome diagnostics group. The combined portfolio would span r...
Microba Director Rombola Lifts Stake via Share Placement
Jul 31, 2026
Microba Life Sciences director Pasquale Rombola has increased his indirect holdings in the company through family and superannuation investment vehicles. The additional shares and options deepen his financial alignment with the company’s lon...
Microba Director Ian Frazer Increases Indirect Stake Through Approved Share Placement
Jul 31, 2026
Microba Life Sciences has disclosed a change in director Ian Frazer’s interests following his participation in Tranche 2 of a recent share placement. Through Frazer Services Pty Ltd as trustee for The Frazer Family Trust, he subscribed for 2...
Microba Raises $5.4m Through Placement and SPP Ahead of FY26 Results
Jul 29, 2026
Microba Life Sciences has completed a capital raising via a two-tranche placement and a share purchase plan, issuing over 108 million new shares at $0.05 each and associated free-attaching options to raise approximately $5.4 million before costs. ...
Microba Life Sciences Issues New Unquoted Options
Jul 29, 2026
Microba Life Sciences Limited has notified the market of the issue of new unquoted equity securities in the form of options. The company is creating 8,089,672 options expiring on July 29, 2029, with an exercise price of $0.075, which are not inten...
Microba Life Sciences Issues Over 100 Million New Unquoted Options
Jul 29, 2026
Microba Life Sciences Limited has notified the market of a substantial issue of unquoted equity securities in the form of options. The new options, totalling 100,004,240, carry an exercise price of $0.0625 and an expiry date of July 29, 2029, and ...
Microba Life Sciences Expands ASX-Quoted Share Base With New Issue
Jul 29, 2026
Microba Life Sciences Limited has applied for quotation of 8,659,785 new ordinary fully paid shares on the ASX, to be issued on July 29, 2026. The securities are being brought onto the market under the company’s existing MAP ticker, in line ...
Microba Life Sciences Issues 8.15 Million Unquoted Options
Jul 29, 2026
Microba Life Sciences Limited has notified the market of a new issue of unquoted equity securities in the form of options. The announcement, lodged with the ASX, outlines an instrument that is separate from its quoted shares and is structured to a...
Microba Life Sciences Seeks ASX Quotation for 8.15 Million New Shares
Jul 29, 2026
Microba Life Sciences Limited has applied for quotation of 8,150,000 new ordinary fully paid shares on the Australian Securities Exchange, effective July 29, 2026. The issuance, lodged via an Appendix 2A application, expands the company’s li...
Microba raises $5.41m to fund expansion of microbiome diagnostics
Jul 28, 2026
Microba Life Sciences has completed a capital raising program combining an institutional placement and a share purchase plan, securing about $5.41 million before costs. The initiative strengthens the company’s balance sheet and underpins exp...
Microba secures strong investor backing for capital-raising authorities
Jul 24, 2026
Microba Life Sciences reported that shareholders approved all resolutions put forward at its 24 July general meeting, with each motion passed by strong poll majorities. The approvals cover ratification of earlier share placements, authorities to i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.